Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

OTHER 2NETWORK 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Vipoma 2Somatostatinoma 2Rectal Neoplasms 2Insulinoma 2Glucagonoma 2Gastrinoma 2Colorectal Neoplasms 2Carcinoma, Islet Cell 2Thymoma 1Neuroendocrine Tumors 1Neoplasms 1Meningioma 1Drug-Related Side Effects and Adverse Reactions 1Diarrhea 1Colonic Neoplasms 1Breast Neoplasms 1Anus Neoplasms 1Adenoma, Islet Cell 1

Interventions

Fluorouracil 29Leucovorin 26Oxaliplatin 25Capecitabine 16Irinotecan 14Cetuximab 10Bevacizumab 9Radiotherapy 8Panitumumab 5Folfox protocol 5Surgical Procedures, Operative 3Levamisole 3Celecoxib 3tremelimumab 2neratinib 2napabucasin 2durvalumab 2cediranib 2aflibercept 2X-Rays 2Tegafur 2Radiofrequency Ablation 2Psychiatric Rehabilitation 2Preoperative Exercise 2Octreotide 2Mitomycin 2Interviews as Topic 2Immunoglobulin G 2Folic Acid 2Floxuridine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Colorectal Neoplasms × Octreotide × Clear all
NCT00003057 2023-06-18

Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer

Eastern Cooperative Oncology Group

Phase 3 Completed
500 enrolled
Gastrointestinal

Colonic Neoplasms, Diarrhea, Rectal Neoplasms, Colorectal Neoplasms

NCT00075868 2015-11-17

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

Radiation Therapy Oncology Group

Phase 3 Completed
233 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡